Business Standard

Indian firms corner more of growing pharma market as MNCs go niche

Indian drug firms are focussing on expanding their salesforce and distri­bution, while getting into trade generics to garner volumes

pharma, medicine, drugs
Premium

Sohini Das Mumbai
Patent expiries, new brand launches, and better geo­grap­hical penetration have helped Indian pharma companies report better growth rates and a higher share of the domestic market in the last five years. Multinational companies (MNCs), on the other hand, are focus­sing on niche therapies, going for licensing deals with Indian firms to get a wider reach, and bringing in more innovative global products.
 
Take Novartis, for instance. “To ensure that we are truly focused and efficient, we have narrowed down on our priority disease areas for India where we can win and create most value,” Amitabh Dube, country president and managing

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in